Betts, Keith A <br/><br/>
An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.  [electronic resource] 

 -  Current medical research and opinion  2016 
 - 721-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; Systematic Review 
<br/><br/><label>ISSN: </label>1473-4877 
<br/><br/><label>Standard No.: </label>10.1185/03007995.2016.1140026  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab--administration & dosage<br/>Antirheumatic Agents--administration & dosage<br/>Arthritis, Psoriatic--drug therapy<br/>Bayes Theorem<br/>Biological Products--administration & dosage<br/>Clinical Trials, Phase III as Topic<br/>Comparative Effectiveness Research<br/>Costs and Cost Analysis<br/>Health Care Costs<br/>Humans<br/>Methotrexate--administration & dosage<br/>Models, Economic<br/>Network Meta-Analysis<br/>Randomized Controlled Trials as Topic<br/>Thalidomide--administration & dosage<br/>Treatment Outcome